Today’s focus

+ About MD Anderson
+ Our Strategy
  • Extending our reach to advance equity
  • Transformational breakthroughs: CAR-NK example
+ Final thoughts
About MD Anderson
MD Anderson is No. 1

$7.7 billion annual revenue

$1.03 billion research investment

23,000+ employees, 1,825+ faculty

170,000+ established patients, 1.5 million outpatient visits

1,600 clinical trials, 9,600+ patients/year

©2022 The University of Texas MD Anderson Cancer Center - Not to be used without permission. For information, please contact SAVirani@mdanderson.org.
MD Anderson’s impact on cancer outcomes

2019 Outcomes Data*
Colorectal Cases
(patients treated 2005-2014)

MDA: Analytical cases

SEER and TCR: Treatment delivered cases only

* Curves produced in 2019 - five years after last patient treated

©2022 The University of Texas MD Anderson Cancer Center - Not to be used without permission. For information, please contact SAVirani@mdanderson.org.
MD Anderson’s impact on science

#1 in total number of awards from NCI

Contributed to 194 of 352 FDA approvals since 2007

Leader in research of innovative cancer treatments
  + Cellular therapy
  + Immunotherapy
  + Microbiome

Translational platforms
  + IACS
  + ORBIT

High impact scientific publications
  + Practice changing
  + 1.6 high impact factor (>10) publications/day since 2012

©2022 The University of Texas MD Anderson Cancer Center - Not to be used without permission. For information, please contact SAVirani@mdanderson.org.
Charting our path forward through our bold Strategy
Synergistic approach to guide our future

OUR STRATEGY

MASTER FACILITIES FRAMEWORK

FINANCIAL PLAN

COMPREHENSIVE FUNDRAISING CAMPAIGN
Our aspiration: maximize our impact on humanity to finally end cancer

- Helping people to a greater degree
- Helping more people

Our impact today

Number of People Helped

Degree of Impact
23 Strategic decisions will guide our future…

**REACH**
- Expand virtual presence
- Become leading health care digital resource for cancer information
  - Expand geographic footprint in Texas
- Create single national partnership model
- Strengthen international relationships with governments and NGOs
- Create best-in-class inbound international patient program
- Build prevention, screening, and survivorship partnerships

**VALUE**
- Implement comprehensive navigation program
- Establish and meet Vizient ranking goal
- Enhance operational excellence
- Explore new reimbursement models
- Diversify revenue streams
- See more early-stage cancer patients
- Increase patient retention
- Integrate goal-concordant care

**BREAKTHROUGHS**
- Build world-class data science program
- Invest in research excellence, talent and the academic mission
- Engage Texas population
- Accelerate and expand clinical trials
- Foster meaningful research collaboration
- Develop innovative education and training programs
- Enhance research infrastructure and drive stewardship
- Connect basic, translational and clinical research
Extending our reach to advance equity
Houston, TX
Largest uninsured population in the U.S.
1 million+ uninsured people

MD Anderson Cancer Center
No. 1 cancer center in the world

MD Anderson Oncology Program at Lyndon B. Johnson hospital deepens our commitment to the underserved by offering multidisciplinary cancer care and cancer control programs
Lyndon B. Johnson Hospital
HARRIS HEALTH SYSTEM

• MD Anderson Oncology Program at LBJ provides cancer care for low-income and medically underserved and undocumented residents of Harris County as the safety net provider
• 17 faculty members in 4 services: Medical Oncology, Gynecologic Oncology, Urologic Oncology, and Orthopedic Oncology

Serving the oncology needs of LBJ’s patients

90% minority | 54% uninsured

Responsible for over

55,000 patient encounters
&

5,700 new patients
FY18-FY21

Trained over

56 Fellows

from FY18 – FY21

©2022 The University of Texas MD Anderson Cancer Center - Not to be used without permission. For information, please contact SAVirani@mdanderson.org.
Enabling equity through our mission

+ **Investment** through $200M quasi-endowment fund for underserved

+ **Access** enhanced through MD Anderson Oncology Program (LBJ Hospital)

+ **Outreach** to Hispanic & African American communities

+ **Delivery** of community-based cancer prevention education programs

+ **Expanding** outreach strategies
  - Sponsorships
  - Direct-to-employer programs
  - Bilingual website pages

©2022 The University of Texas MD Anderson Cancer Center - Not to be used without permission. For information, please contact SAVirani@mdanderson.org.
MD Anderson
Be Well Communities™

Place-based strategy for cancer prevention and control, working with communities to promote wellness and stop cancer before it starts

FOCUS AREAS

Healthy Eating  Active Living  Sun Safety

Healthy Eating  Active Living  Sun Safety

IMPACT

4.5 million+
pounds of healthy food distributed to families

8,500+
college students and staff received tobacco-free resources

50+
local, regional and state organizations actively engaged in community steering committees

70,000+
students participated in health and physical activity programs

27+
Sunshades installed at city parks, schools and college campuses

©2022 The University of Texas MD Anderson Cancer Center - Not to be used without permission. For information, please contact SAVirani@mdanderson.org.
Transformational breakthroughs: CAR-NK example
Lymphocytes (T Cells) are engineered to recognize and kill ‘camouflaged tumor’ cells through the expression of Chimeric Antigen Receptors – CARs
CAR T-Cell Therapy

- Patient-specific cells only
- Expensive to manufacture and administer
- Significant Inpatient time and cost
- Significant risk for toxicity
- Risk of graft-versus-host-disease (GVHD)

Societal Need for Better Therapies

- Off-the-shelf product (allogenic cells)
- Lower cost to manufacture and administer
- Outpatient therapy option
- Less toxicity potential
- Freedom from GVHD

Disruptive Status: CAR NK-Cell Therapy

- Off the shelf, sourced from cord blood
- Significantly lower cost – can manufacture >100 doses from one cord unit
- Outpatient accessibility
- No toxicity to date
- No risk for GVHD

©2022 The University of Texas MD Anderson Cancer Center - Not to be used without permission. For information, please contact SAVirani@mdanderson.org.
First-in-human clinical trial of CAR NK cells in lymphoid cancer

Whole body PET

PET scan uses a special dye containing radioactive tracers. The tracer will collect in areas of higher metabolic activity, such as cancer cells, but also in some normal tissue such as the brain, kidneys and bladder.
MD Anderson and Takeda Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers.

Under the agreement, Takeda will receive access to MD Anderson’s CAR NK platform and the exclusive rights to develop and commercialize up to four programs, including a CD19-targeted CAR NK-cell therapy and a B-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy. Takeda and MD Anderson also will conduct a research collaboration to further develop these CAR NK programs.
Final Thoughts

+ Through our Strategy, MD Anderson is working to maximize our impact on humanity to finally end cancer.

+ Our deep commitment to the underserved is driving our strategic efforts to extend our reach.

+ We are creating solutions defined by disruptive biological innovation that can quickly reach the bedside.